Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Bin Wu; Qiang Zhang; Jie Sun

doi:10.1186/s40425-018-0440-9

Home SearchPaper Details

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Bin Wu, Qiang Zhang, Jie Sun

BMJ (2018) • Volume 6, Issue 1, Pages 124-124

PDF Available

Abstract

Nivolumab plus ipilimumab as first-line treatment could gain more health benefits for advanced RCC in comparison with standard sunitinib, which is considered to be cost-effective in the US and China but not in the UK.

Quick Actions

Read Full Paper

Publication Info

DOI

10.1186/s40425-018-0440-9

Language

English

Topic

Renal cell carcinoma treatment

Keywords

Nivolumab, Ipilimumab, Medicine, Sunitinib, Renal cell carcinoma, Internal medicine, Oncology, Cost effectiveness, Cancer, Immunotherapy

Published

November 20, 2018

Citations

112 citations

FWCI

8.64

External Resources

DOI Link OpenAlex

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

An assessment of the impact of thimerosal on childhood neurodevelopmental disorders

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Hepatoprotective Effect of Green Tea (Camellia sinensis) Extract against Tamoxifen-induced Liver Injury in Rats

Suggested Papers

Suggested Papers

An assessment of the impact of thimerosal on childhood neurodevelopmental disorders

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Hepatoprotective Effect of Green Tea (Camellia sinensis) Extract against Tamoxifen-induced Liver Injury in Rats